Plain-English translation of NCT06904482 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to stem cell transplantation for patients with serious blood cancers like leukemia and myelodysplastic syndrome. Instead of waiting for a perfectly matched donor (which can be especially difficult for Black, Asian, and Hispanic patients), this study uses two grafts together: one from a family member who is a partial match, and one from preserved cord blood. The goal is to make this combination safe and effective while giving more patients access to lifesaving transplant treatment.
Finding a perfectly matched bone marrow or stem cell donor is very difficult, especially for patients of color—sometimes impossible within a reasonable timeframe. This trial exists to see if combining two partially matched grafts can work just as well, making transplants available to more patients who urgently need them.
You likely qualify if…
You likely don't qualify if…
You would receive intense chemotherapy to prepare your body for the transplant, followed by infusion of stem cells from your partially matched family donor. Several days later, after a specific chemotherapy drug (cyclophosphamide) is given to reduce transplant rejection risk, you would receive the cord blood stem cells. You would then be monitored closely in the hospital and as an outpatient for months afterward to watch for complications and track how well the transplant is working to control your cancer.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Case Comprehensive Cancer Center
Enrollment target
~36 participants
Started
August 2025
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Leland Metheny, MD
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.